| Vol. 15.01 – 13 January, 2021 |
| |
|
|
| Investigators demonstrated that STING to be a critical regulator of nociception through type-I interferon signaling in peripheral nociceptive sensory neurons. [Nature] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| To identify and characterize selectively vulnerable neuronal populations, the authors used single-nucleus RNA sequencing to profile the caudal entorhinal cortex and the superior frontal gyrus—brain regions where neurofibrillary inclusions and neuronal loss occurred early and late in Alzheimer’s disease (AD), respectively—from postmortem brains spanning the progression of AD-type tau neurofibrillary pathology. [Nature Neuroscience] |
|
|
|
| Researchers harnessed the structural and trafficking properties of an atoxic derivative of botulinum neurotoxin (BoNT) to transport a function-blocking single-domain antibody into the neuronal cytosol where it could inhibit BoNT serotype A molecular toxicity. [Science Translational Medicine] |
|
|
|
| Scientists generated profiles for the three regulatory layers from developmentally and regionally distinct subpopulations of neurons from the mouse hippocampus and broader nervous system. [Nature Communications] |
|
|
|
| The authors report an efficient, network-based drug-screening platform developed by integrating mathematical modeling and the pathological features of Alzheimer’s disease with human induced pluripotent stem cell-derived cerebral organoids, including CRISPR-Cas9-edited isogenic lines. [Nature Communications] |
|
|
|
| Scientists used three independent approaches to probe the capacity of SARS-CoV-2 to infect the brain. Using human brain organoids, they observed clear evidence of infection with accompanying metabolic changes in infected and neighboring neurons. [Journal of Experimental Medicine] |
|
|
|
| Researchers detailed an accurate, step-by-step workflow that includes in vitro microglia differentiation from human pluripotent stem cells, transplantation into the mouse brain and quantitative analysis of engraftment. [Nature Protocols] |
|
|
|
| Scientists tested whether anaplastic lymphoma kinase AL2 (ALKAL2) ligand could potentiate neuroblastoma progression in the absence of ALK mutation [EMBO Journal] |
|
|
|
| To explore what signaling pathways may be involved, investigators employed heterologous synapse formation assays in which a synaptic adhesion molecule expressed in a nonneuronal cell induced pre- or postsynaptic specializations in cocultured neurons. [Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Scientists present an in vitro model of the peripheral nervous system by establishing a coculture model of motor neurons and Schwann cells in a 3D environment in a microengineered extracellular matrix hydrogel scaffold. [NPG Asia Materials] |
|
|
|
| Expression data from developmental and adult neurogenesis showed relative enrichment of Notch and γ-secretase expression in stem cells, whereas expression of APP and β-secretase was enriched in neurons. [Cell Reports] |
|
|
|
| Researchers observed that monocarboxylate transporter 1 (MCT1) loss from oligodendrocyte lineage cells was dispensable for normal myelination and axonal energy homeostasis early in life. [Cell Reports] |
|
|
|
|
| The authors propose a conceptual framework for how combinations of synaptic protein isoforms act as ‘senders’ and ‘readers’ to instruct synapse formation and the acquisition of cell type-specific and synapse-specific functional properties. [Nature Reviews Neuroscience] |
|
|
|
| Scientists consider how knowledge of E3 ligase biology may be used for future therapeutic interventions in glioblastoma, including the use of blood-brain barrier permeable proteolysis targeting chimeras. [Cell Death & Differentiation] |
|
|
|
| Investigators summarize the current knowledge on the role of microglia in viral encephalitis, propose questions to be answered in the future and suggest possible therapeutic targets. [Cellular & Molecular Immunology] |
|
|
|
|
| Cognito Therapeutic. Inc. announced its lead product has received Breakthrough Device Designation from the FDA for the treatment of cognitive and functional symptoms associated with Alzheimer’s disease. [Cognito Therapeutic. Inc. (Business Wire, Inc.)] |
|
|
|
| OX2 Therapeutics, Inc. announced that they treated their first patient in a Phase I human trial of a new treatment developed to combat recurrent high-grade brain tumors. [OX2 Therapeutics, Inc. (Business Wire, Inc.)] |
|
|
|
|
| January 25 – 28, 2021 Virtual |
|
|
|
|
|
| St. Jude Children’s Research Hospital – Memphis, Tennessee, United States |
|
|
|
| University College London – London, England, United Kingdom |
|
|
|
| Hospital for Sick Children; University of Toronto – Toronto, Ontario, Canada |
|
|
|
| Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| Luxembourg Institute of Healtht – Luxembourg, Luxembourg |
|
|
|
|